Similarly, in animal models of PD, pharmacological inhibitors of c‐Abl reduce the formation of pY39 α‐synuclein and Lewy pathology, reduce mitochondrial dysfunction, and rescue DA neurons and motor function in a dose‐dependent manner. Here, ABL1 is linked to Parkinson disease.